The National Company Law Tribunal (NCLT), Amravati Special Branch, has scheduled the next hearing for Laurus Labs 's Composite Scheme of Arrangement for September 10, 2026. This procedural milestone advances the restructuring plan involving the company’s wholly-owned subsidiaries, Laurus Synthesis Private Limited (LSPL) and Sriam Labs Private Limited. The tribunal’s order, pronounced on July 24, 2026, directs the petitioner companies to serve formal notices to concerned authorities, regulators, and stakeholders in Form No. CAA-3.

Scheme Structure and Objectives

The Composite Scheme of Arrangement is structured under Sections 230 to 232 of the Companies Act, 2013, and the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016. The plan involves two primary corporate actions:

1. Demerger: The Identified Business Undertaking, specifically Unit-1 of LSPL, will be demerged into Sriam Labs Private Limited, a wholly-owned subsidiary of Laurus Labs Limited.
2. Amalgamation: The remaining business undertakings of LSPL (the entire entity excluding Unit-1) will be amalgamated with Laurus Labs Limited, the transferee company.

LSPL serves as the transferor or demerged company, while Sriam Labs acts as the resulting company. Laurus Labs Limited functions as the transferee company. The petitioners collectively refer to these entities as the Petitioner Companies.

Regulatory Compliance and Timeline

Laurus Labs Limited disclosed this development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure references previous communications dated August 21, 2025, September 05, 2025, February 24, 2026, and April 07, 2026, which outlined earlier stages of the scheme’s progression.

The NCLT order was uploaded to the official tribunal website on July 24, 2026. G. Venkateswar Reddy, Company Secretary & Compliance Officer of Laurus Labs Limited, signed the disclosure on behalf of the company. The filing confirms that the next date of hearing is fixed for consideration of the Scheme, marking a key step toward final approval.

What the Numbers Show

While no financial metrics are disclosed in this specific regulatory update, the structural separation of Unit-1 from LSPL suggests a strategic focus on isolating specific business operations within Sriam Labs. The amalgamation of the remainder with the parent entity indicates an intent to streamline the corporate structure by consolidating non-demerged assets directly under Laurus Labs Limited. This reorganization may impact future reporting lines and operational oversight for the identified units, though specific financial impacts remain undisclosed at this stage.

Laurus Labs has outlined a clear strategic direction, expressing confidence that the CDMO (Contract Development and Manufacturing Organisation) segment will contribute at least 50% of the company's total revenue by FY30. This signals a deliberate pivot towards higher-value, innovation-driven manufacturing services as a core growth driver for the business over the medium term.

CDMO Revenue Target and Strategic Ambition

The company's stated goal of deriving at least 50% of total revenue from the CDMO segment by FY30 underscores its commitment to deepening capabilities in contract development and manufacturing. This segment is increasingly being positioned as the primary engine of long-term revenue growth for Laurus Labs, reflecting a broader industry trend of pharmaceutical companies expanding their CDMO offerings to global innovator clients.

Key Financial Metrics and Targets

Alongside its revenue mix ambitions, Laurus Labs has also set specific financial efficiency targets. The following table summarises the key metrics and goals disclosed by the company:

The company's initial target for the asset turnover ratio is above 1.0, reflecting a focus on improving capital utilisation efficiency. Meanwhile, the Return on Capital Employed (ROCE) currently stands at 19%, with the company aiming to improve this to 23%.

Capital Expenditure Impact on ROCE Timeline

Management has been candid about the timeline for achieving the 23% ROCE target, noting that the improvement will take time. The primary reason cited is the significant capital expenditure being undertaken during the current year. Large-scale capex investments, while essential for building future capacity and capabilities, typically weigh on near-term ROCE metrics as the capital base expands ahead of corresponding revenue generation.

Summary

Laurus Labs has articulated a well-defined financial roadmap anchored by three key objectives: growing the CDMO segment to at least 50% of total revenue by FY30, achieving an asset turnover ratio above 1.0, and improving ROCE from the current 19% to 23%. The company has transparently flagged that near-term ROCE progression will be constrained by substantial capital expenditure commitments in the current year, even as it builds the foundation for longer-term financial performance improvement.